Home Cart Sign in  
Chemical Structure| 57294-38-9 Chemical Structure| 57294-38-9
Chemical Structure| 57294-38-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

N-Boc-γ-aminobutyric acid is a protected γ-aminobutyric acid derivative with the amino group protected by tert-butoxycarbonyl (Boc), commonly used in peptide synthesis and as a pharmaceutical intermediate.

Synonyms: Boc-GABA-OH

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Rathje, Oliver H. ; Perryman, Lara ; Payne, Richard J. ; Hamprecht, Dieter W. ;

Abstract: Mixed Lineage Kinase domain-Like pseudokinase (MLKL) is implicated in a broad range of diseases due to its role as the ultimate effector of necroptosis and has therefore emerged as an attractive drug target. Here, we describe the development of PROteolysis TArgeting Chimeras (PROTACs) as a novel approach to knock down MLKL through chem. means. A series of candidate degraders were synthesized from a high-affinity pyrazole carboxamide-based MLKL ligand leading to the identification of a PROTAC mol. that effectively degraded MLKL and completely abrogated cell death in a TSZ model of necroptosis. By leveraging the innate ability of these PROTACs to degrade MLKL in a dose-dependent manner, the quant. relationship between MLKL levels and necroptosis was interrogated. This work demonstrates the feasibility of targeting MLKL using a PROTAC approach and provides a powerful tool to further our understanding of the role of MLKL within the necroptotic pathway.

Alternative Products

Product Details of N-Boc-γ-aminobutyric acid

CAS No. :57294-38-9
Formula : C9H17NO4
M.W : 203.24
SMILES Code : O(C(C)(C)C)C(=O)NCCCC(=O)O
Synonyms :
Boc-GABA-OH
MDL No. :MFCD00037313
InChI Key :HIDJWBGOQFTDLU-UHFFFAOYSA-N
Pubchem ID :294894

Safety of N-Boc-γ-aminobutyric acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of N-Boc-γ-aminobutyric acid

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 57294-38-9 ]

[ 57294-38-9 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 15761-38-3 ]
  • [ 57294-38-9 ]
  • [ 95753-55-2 ]
  • [ 267410-86-6 ]
  • (S)-2-[(S)-2-(4-{3-[3-(3-Amino-propylamino)-propylamino]-propylamino}-butyrylamino)-3-(4-nitro-phenyl)-propionylamino]-propionic acid [ No CAS ]
  • 2
  • [ 15761-38-3 ]
  • [ 57294-38-9 ]
  • [ 95753-55-2 ]
  • (S)-2-[(S)-2-(4-Amino-butyrylamino)-3-(4-nitro-phenyl)-propionylamino]-propionic acid [ No CAS ]
  • 3
  • [ 15761-38-3 ]
  • [ 57294-38-9 ]
  • [ 123-72-8 ]
  • [ 95753-55-2 ]
  • [ 267410-86-6 ]
  • (S)-2-[(S)-2-[4-({3-[(3-Amino-propyl)-butyl-amino]-propyl}-butyl-amino)-butyrylamino]-3-(4-nitro-phenyl)-propionylamino]-propionic acid [ No CAS ]
  • 4
  • [ 295-64-7 ]
  • [ 57294-38-9 ]
  • [ 266000-49-1 ]
  • 5
  • [ 57294-38-9 ]
  • [ 13836-37-8 ]
  • [ 37736-82-6 ]
  • [ 117014-32-1 ]
  • [ 84624-27-1 ]
  • [ 18942-49-9 ]
  • [ 108-24-7 ]
  • [ 47355-10-2 ]
  • [ 25024-53-7 ]
  • Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH<SUB>2 </SUB> [ No CAS ]
YieldReaction ConditionsOperation in experiment
The title peptide was synthesized on an Applied Biosystems (Foster City, Calif.) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See Schnolzer, et al., Int. J. Peptide Protein Res., 40:180 (1992). 4-methylbenzhydrylamine (MBHA) resin (Peninsula, Belmont, Calif.) with the substitution of 0.91 mmol/g was used. The Boc amino acids (Novabiochem, San Diego, Calif. and Chem-Impex, Wood Dale, Ill.) used were: Boc-Cha-OH, Boc-Asp(OFm)-OH, Boc-His(DNP)-OH, Boc-D-Phe-OH, Boc-Arg(Tos)-OH, <strong>[47355-10-2]<strong>[47355-10-2]Boc-Trp(For)</strong>-OH</strong>, Boc-Gaba-OH, and Boc-Lys(Fmoc)-OH. The synthesis was carried out on a 0.20 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2×1 minute. Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 minutes. (0223) At the end of the assembly of Boc-Asp(OFm)-His(DNP)-D-Phe-Arg(Tos)-Trp(For)-Gaba-Lys(Fmoc)-MBHA, the peptide-resin was transferred into a reaction vessel on a shaker. The resin was treated twice with 25% piperidine in DMF for 15 minutes per session, washed with DMF, and shaken with bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrOP) (6 eq, 0.3 mmol), DIEA (1 mL), and 4-(dimethylamino)pyridine (DMAP) (24 mg) in DMF (2 mL) for 12 hours. After washing with DMF, the resin was treated twice with 100% TFA for 2 minutes per treatment, washed with DMF and DCM, and then dried under reduced pressure. One fourth of the peptide-resin (0.05 mmol) was used for the next coupling with Boc-Cha-OH (10 eq, 0.5 mmol) in the presence of HBTU (9 eq, 0.45 mmol) and DIEA (0.25 mL) in DMF for 10 minutes. After the deprotection with 100% TFA in two sessions lasting approximately 2 minutes each, the peptide-resin was then washed with DMF. The final capping step was done by shaking the resin with acetic anhydride (40 eq, 2.0 mmol) and DIEA (20 eq, 1.0 mmol) in DMF for 1 hour. After washing with DMF, the resin was treated twice with a solution of 20% mercaptoethanol/10% DIEA in DMF, each treatment lasting approximately 30 minutes, to remove the DNP group on the Histidine side chain. The formyl group on the side chain of Tryptophan was removed by shaking with a solution of 15% ethanolamine/15% water/70% DMF twice for 30 minutes per shaking. The peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (30 mg) at 0 C. for 75 minutes. HF was removed by a flow of nitrogen. The residue was washed with ether (6×10 mL) and extracted with 4N HOAc (6×10 mL). (0224) The peptide mixture in the aqueous extract was purified on reverse-phase preparative high pressure liquid chromatography (HPLC) using a reverse phase VYDAC C18 column (Nest Group, Southborough, Mass.). The column was eluted with a linear gradient (10% to 50% of solution B over 40 minutes) at a flow rate of 10 mL/minute (Solution A=water containing 0.1% TFA; Solution B=acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 5.1 mg of a white solid was obtained. Yield was 8.9%. Purity was 94.5% based on analytical HPLC analysis. Electro-spray mass spectrometer (MS(ES))S analysis gave the molecular weight at 1148.5 (in agreement with the calculated molecular weight of 1148.3). (0225) Other peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables 1A and 1B. (0226) Other peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables 1A and 1B.
 

Historical Records

Categories